Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
Khaled Musallam, Group Chief Research Officer Burjeel Holdings, Adj. Prof. Khalifa University and Weill Cornell Medicine (NY), shared on LinkedIn:
”Pleased to share results from our de-LIGHT study out now in the British Journal of Haematology. What makes this data special and what’s its added value:
- Most studies evaluating the impact of anemia and iron overload on morbidity and mortality outcomes in beta-thalassemia (including those from our group) used spot indices or followed patients over short or defined periods of time. In de-LIGHT, it took tremendous effort but we were able to capture a lifetime observation since diagnosis looking at anemia/iron vs outcomes over a median follow up of 38 years in 500+ patients
- We defined patients as having NTDT or TDT based on lifetime exposure to transfusions (rather than their status ‘now’ or in the past 6 months)
- We used a lifetime anemia and iron control index (LAICI) defined based on adherence to TIF guidelines recommendations in NTDT and TDT. This was significantly and independently associated with overall survival and incidence of various morbidities.
Thalassemia treatment is lifelong, and evidence-based, optimal management of anemia and iron overload should persist over the entire disease course and cannot be sporadic.”
Read the full article here.
Article: Impact of lifetime anaemia and iron control on outcomes in β-thalassaemia: Data from the longitudinal de-LIGHT study
Authors: Khaled Musallam, Angela Vitrano, Alessandro Inzerillo, Rosario Di Maggio, Rita Barone, Antonino Giangreco, Maria Concetta Renda, Emanuela Fecarotta, Antonio Troia, Antonino Giambona, Giovan Battista Ruffo, Efthymia Vlachaki, Theodora M. Venou, Paolo Ricchi, Brunella Ziello, Marilena Serra, Elena Colizzi, Filomena Longo, Martina Culcasi, Aurelio Maggio

Stay updated on the latest scientific advances in the field of hematology with Hemostasis Today.
-
Dec 12, 2025, 23:51Don’t Miss: IACH Post ASH 2025 Roundtable Debate
-
Dec 12, 2025, 23:37C-Reactive Protein and Cardiovascular Risk in the General Population: A European Heart Journal Study by Berkan Kurt et al.
-
Dec 12, 2025, 23:23Alta Schutte and Colleagues at National Hypertension Taskforce: Driving Single-Pill Therapy for Hypertension and More
-
Dec 12, 2025, 22:27Normal Counts, High Risk: Abdul Mannan Breaks Down JAK2 + Splanchnic Vein Thrombosis
-
Dec 12, 2025, 14:478 Posts Not to Miss From the ASH 2025 – Marc Carrier
-
Dec 12, 2025, 10:17Alyssa George on Clinical and Economic Impact of a Eptacog Beta
-
Dec 12, 2025, 09:53Ivan Budnik Awarded AHA Postdoctoral Fellowship! Aiming to Improve DVT Long-term Outcomes
-
Dec 12, 2025, 09:34Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
-
Dec 12, 2025, 09:31Aravind Palraj: A Quick Guide to What Clinicians Actually Need
